China and Taiwan look to closer regulatory ties under new cross-strait pact
This article was originally published in Scrip
China and Taiwan may still have their political differences but they are moving steadily towards increased co-operation and regulatory harmonisation in the pharmaceutical sector under a recent bilateral agreement designed to cut the unnecessary duplication of studies and improve product quality.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.